{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:11:38Z","timestamp":1788826298161,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ad.2020.03.001","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T17:03:44Z","timestamp":1592586224000},"page":"639-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Uso de la espironolactona en dermatolog\u00eda: acn\u00e9, hidradenitis supurativa, alopecia femenina e hirsutismo"],"prefix":"10.1016","volume":"111","author":[{"given":"P.","family":"Vargas-Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2020.03.001_bib0355","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaad.2018.08.061","article-title":"Androgens in women: Hormone-modulating therapies for skin disease","volume":"80","author":"Azarchi","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0360","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jaad.2018.08.062","article-title":"Androgens in women: Androgen-mediated skin disease and patient evaluation","volume":"80","author":"Bienenfeld","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0365","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.mce.2017.09.009","article-title":"Androgens and androgen receptor action in skin and hair follicles","volume":"465","author":"Ceruti","year":"2018","journal-title":"Mol Cell Endocrinol."},{"key":"10.1016\/j.ad.2020.03.001_bib0370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2007-961807","article-title":"Sexual hormones in human skin","volume":"39","author":"Zouboulis","year":"2007","journal-title":"Horm Metab Res."},{"key":"10.1016\/j.ad.2020.03.001_bib0375","first-page":"629","article-title":"Localization of sex steroid receptors in human skin","volume":"19","author":"Pelletier","year":"2004","journal-title":"Histol Histopathol."},{"key":"10.1016\/j.ad.2020.03.001_bib0380","first-page":"3","article-title":"Androgen receptor structure function and biology: From bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"Clin Biochem Rev."},{"key":"10.1016\/j.ad.2020.03.001_bib0385","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00105-013-2597-y","article-title":"[Spironolactone in dermatological treatment. On and off label indications]","volume":"64","author":"Salavastru","year":"2013","journal-title":"Hautarzt."},{"key":"10.1016\/j.ad.2020.03.001_bib0390","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","article-title":"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture","volume":"31","author":"Luthy","year":"1988","journal-title":"J Steroid Biochem."},{"key":"10.1016\/j.ad.2020.03.001_bib0395","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0022-4731(85)90236-5","article-title":"The effect of spironolactone on genital skin 5 alpha-reductase activity","volume":"23","author":"Serafini","year":"1985","journal-title":"J Steroid Biochem."},{"key":"10.1016\/j.ad.2020.03.001_bib0400","series-title":"Comprehensive dermatologic drug therapy","author":"Wolverton","year":"2013"},{"key":"10.1016\/j.ad.2020.03.001_bib0405","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","article-title":"Oral spironolactone for acne vulgaris in adult females: A hybrid systematic review","volume":"18","author":"Layton","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0410","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaad.2018.09.055","article-title":"Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments","volume":"80","author":"Barbieri","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0415","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","volume":"151","author":"Plovanich","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0420","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2007.09.024","article-title":"Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone","volume":"58","author":"Krunic","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0425","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijwd.2019.04.024","article-title":"Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program","volume":"5","author":"Thiede","year":"2019","journal-title":"Int J Womens Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0430","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review","volume":"80","author":"Liszewski","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0435","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: Retrospective, matched cohort study","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ."},{"key":"10.1016\/j.ad.2020.03.001_bib0440","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.ad.2020.03.001_bib0445","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bcp.13152","article-title":"Spironolactone use and risk of incident cancers: A retrospective, matched cohort study","volume":"83","author":"Mackenzie","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.ad.2020.03.001_bib0450","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0455","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaad.2017.04.016","article-title":"Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: A retrospective analysis, 2004-2013","volume":"77","author":"Barbieri","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0460","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","article-title":"Systematic review of antibiotic resistance in acne: An increasing topical and oral threat","volume":"16","author":"Walsh","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.ad.2020.03.001_bib0465","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","volume":"111","author":"Goodfellow","year":"1984","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0470","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","volume":"115","author":"Muhlemann","year":"1986","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0475","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clindermatol.2009.03.006","article-title":"Hormonal therapy for acne: Why not as first line therapy? Facts and controversies","volume":"28","author":"Katsambas","year":"2010","journal-title":"Clin Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0480","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1067\/mjd.2000.105557","article-title":"Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients","volume":"43","author":"Shaw","year":"2000","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0485","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2005.01072.x","article-title":"Effects and side-effects of spironolactone therapy in women with acne","volume":"19","author":"Yemisci","year":"2005","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2020.03.001_bib0490","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00266-006-0081-0","article-title":"Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians","volume":"30","author":"Sato","year":"2006","journal-title":"Aesthetic Plast Surg."},{"key":"10.1016\/j.ad.2020.03.001_bib0495","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000471799","article-title":"Spironolactone for the treatment of acne: A 4-year retrospective study","volume":"233","author":"Grandhi","year":"2017","journal-title":"Dermatology (Basel)."},{"key":"10.1016\/j.ad.2020.03.001_bib0500","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijwd.2016.12.002","article-title":"Spironolactone for the treatment of acne in women, a retrospective study of 110 patients","volume":"3","author":"Charny","year":"2017","journal-title":"Int J Womens Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0505","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1684\/ejd.2017.3062","article-title":"Adult female acne treated with spironolactone: A retrospective data review of 70 cases","volume":"27","author":"Isvy-Joubert","year":"2017","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0510","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40257-018-0349-6","article-title":"The use of hormonal antiandrogen therapy in female patients with acne: A 10-year retrospective study","volume":"19","author":"Park","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0515","first-page":"632","article-title":"Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: A retrospective cohort study 2010-2016","volume":"17","author":"Barbieri","year":"2018","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0520","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaad.2019.03.036","article-title":"Real-world drug usage survival of spironolactone versus oral antibiotics for the management of female patients with acne","volume":"81","author":"Barbieri","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0525","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000194.pub2","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ad.2020.03.001_bib0530","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","article-title":"Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne","volume":"78","author":"Thiboutot","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0535","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/jdv.13776","article-title":"European evidence-based (S3) guideline for the treatment of acne \u2014update 2016 \u2014short version","volume":"30","author":"Nast","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2020.03.001_bib0540","first-page":"37","article-title":"Oral spironolactone in post-teenage female patients with acne vulgaris: Practical considerations for the clinician based on current data and clinical experience","volume":"5","author":"Kim","year":"2012","journal-title":"J Clin Aesthet Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0545","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijwd.2017.02.018","article-title":"A review of hormone-based therapies to treat adult acne vulgaris in women","volume":"3","author":"Trivedi","year":"2017","journal-title":"Int J Womens Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0550","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","article-title":"Pathophysiology of hidradenitis suppurativa: An update","volume":"73","author":"Prens","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0555","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: From pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0560","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.det.2015.08.005","article-title":"Endocrinologic aspects of hidradenitis suppurativa","volume":"34","author":"Karagiannidis","year":"2016","journal-title":"Dermatol Clin."},{"key":"10.1016\/j.ad.2020.03.001_bib0565","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2016.07.024","article-title":"Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study","volume":"76","author":"Vossen","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0570","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/7750.2007.00019","article-title":"Hidradenitis suppurativa in 64 female patients: Retrospective study comparing oral antibiotics and antiandrogen therapy","volume":"11","author":"Kraft","year":"2007","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.ad.2020.03.001_bib0575","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0580","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0585","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1203475418823529","article-title":"Combination therapies for hidradenitis suppurativa: A retrospective chart review of 31 patients","volume":"23","author":"McPhie","year":"2019","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.ad.2020.03.001_bib0590","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40257-019-00442-w","article-title":"Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data","volume":"20","author":"Nikolakis","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0595","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.0022-202x.2001.01670.x","article-title":"Molecular mechanisms regulating hair follicle development","volume":"118","author":"Millar","year":"2002","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0600","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.det.2010.03.011","article-title":"Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss","volume":"28","author":"Rathnayake","year":"2010","journal-title":"Dermatol Clin."},{"key":"10.1016\/j.ad.2020.03.001_bib0605","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","article-title":"Treatment of female pattern hair loss with oral antiandrogens","volume":"152","author":"Sinclair","year":"2005","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0610","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2133.1985.tb02305.x","article-title":"Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia","volume":"112","author":"Burke","year":"1985","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0615","first-page":"201","article-title":"Effectiveness of spironolactone in reducing hair loss in women with androgenetic alopeciaJT Journal of Investigative Medicine","volume":"61","author":"Slaught","year":"2013"},{"key":"10.1016\/j.ad.2020.03.001_bib0620","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2015.06.063","article-title":"Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy","volume":"73","author":"Famenini","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0625","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijd.13838","article-title":"Female pattern hair loss: A pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone","volume":"57","author":"Sinclair","year":"2018","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0630","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1440-0960.2007.00332.x","article-title":"Treatment of female pattern hair loss with a combination of spironolactone and minoxidil","volume":"48","author":"Hoedemaker","year":"2007","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0635","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jamadermatol.2016.5790","article-title":"Interventions for female pattern hair loss","volume":"153","author":"Van Zuuren","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0640","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/ijt.ijt_46_18","article-title":"A retrospective analysis of efficacy and safety of intralesional triamcinolone injections in the treatment of frontal fibrosing alopecia either as monotherapy or as a concomitant therapy","volume":"10","author":"Gkini","year":"2018","journal-title":"Int J Trichology."},{"key":"10.1016\/j.ad.2020.03.001_bib0645","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2019.03.079","article-title":"Medical therapy for frontal fibrosing alopecia: A review and clinical approach","volume":"81","author":"Ho","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0650","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40257-014-0078-4","article-title":"Hirsutism: An evidence-based treatment update","volume":"15","author":"Somani","year":"2014","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0655","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjd.14486","article-title":"Interventions for hirsutism excluding laser and photoepilation therapy alone: Abridged Cochrane systematic review including GRADE assessments","volume":"175","author":"Van Zuuren","year":"2016","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2020.03.001_bib0660","first-page":"89","article-title":"Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ad.2020.03.001_bib0665","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0015-0282(16)56634-5","article-title":"Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism","volume":"61","author":"Erenus","year":"1994","journal-title":"Fertil Steril."},{"key":"10.1016\/j.ad.2020.03.001_bib0670","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2265.2007.03105.x","article-title":"A systematic review of commonly used medical treatments for hirsutism in women","volume":"68","author":"Koulouri","year":"2008","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.ad.2020.03.001_bib0675","first-page":"233","article-title":"A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women","volume":"80","author":"Wong","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ad.2020.03.001_bib0680","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.2003-031780","article-title":"Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study","volume":"89","author":"Ganie","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ad.2020.03.001_bib0685","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0015-0282(16)58441-6","article-title":"Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism","volume":"66","author":"Erenus","year":"1996","journal-title":"Fertil Steril."},{"key":"10.1016\/j.ad.2020.03.001_bib0690","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/09546634.2010.519766","article-title":"Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens","volume":"23","author":"Kelekci","year":"2012","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.ad.2020.03.001_bib0695","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/eje.0.1500351","article-title":"A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism","volume":"150","author":"Kele\u015ftimur","year":"2004","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.ad.2020.03.001_bib0700","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0015-0282(02)04294-2","article-title":"Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism","volume":"78","author":"Unl\u00fchizarci","year":"2002","journal-title":"Fertil Steril."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731020301277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731020301277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:10:00Z","timestamp":1757553000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731020301277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0001731020301277"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2020.03.001","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uso de la espironolactona en dermatolog\u00eda: acn\u00e9, hidradenitis supurativa, alopecia femenina e hirsutismo","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2020.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}